Short Interest in Bavarian Nordic A/S (OTCMKTS:BVNRY) Increases By 39.6%

Bavarian Nordic A/S (OTCMKTS:BVNRY) saw a significant increase in short interest in February. As of February 28th, there was short interest totalling 7,400 shares, an increase of 39.6% from the February 13th total of 5,300 shares. Based on an average trading volume of 15,500 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.0% of the shares of the company are short sold.

Bavarian Nordic A/S Price Performance

Bavarian Nordic A/S stock opened at $8.10 on Friday. The stock has a market capitalization of $1.92 billion, a PE ratio of 11.74 and a beta of 1.83. Bavarian Nordic A/S has a 12 month low of $6.86 and a 12 month high of $14.60. The business has a 50 day simple moving average of $8.42 and a 200-day simple moving average of $9.67.

Bavarian Nordic A/S (OTCMKTS:BVNRY) last posted its quarterly earnings data on Wednesday, March 5th. The company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.40 by $0.07. The business had revenue of $299.48 million during the quarter, compared to analysts’ expectations of $264.06 million. Bavarian Nordic A/S had a return on equity of 10.65% and a net margin of 18.33%. On average, equities research analysts anticipate that Bavarian Nordic A/S will post 0.67 EPS for the current fiscal year.

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.